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Kaposi’s sarcoma-associated herpesvirus (KSHV or human herpesvirus 8) is a novel gammaherpesvirus
implicated in the cause of Kaposi’s sarcoma and certain malignancies of lymphatic origin. One of the candidate
genes possibly involved in promoting tumor development is an open reading frame (ORF) with sequence
similarity to human type D cyclin genes. This cyclin-like gene, when expressed in tissue culture cells, promotes
phosphorylation and inactivation of the retinoblastoma tumor suppressor protein and thereby may result in
deregulation of cell division control. We report here the biochemical characterization of this cyclin (KSHV-cyc)
and the kinase activity that it elicits upon expression in tissue culture cells. We demonstrate that the kinase
activity associated with KSHV-cyc is sensitive to the cdk inhibitor p27 (KIP) and due to activation of cdk6.
However, in contrast to cdk6 activated by cellular type D cyclins, the cdk6 activated by KSHV-cyc is capable
of phosphorylating not only the retinoblastoma protein but also histone H1. This finding implies that activa-
tion by KSHV-cyc alters the substrate preference of this cdk. This may have important physiological conse-
quences in that the kinase activity triggered by this viral cyclin may abrogate cell cycle checkpoints in addition
to those targeted by cellular cyclin D-cdk6 kinase.
Kaposi’s sarcoma (KS) is a vascular tumor characterized by
multicentric lesions that most likely originate from hyperpro-
liferation of endothelial cells (reviewed in reference 55). Clas-
sic KS, which presents in elderly men of Mediterranean origin,
and endemic KS, found in human immunodeficiency virus
(HIV)-negative individuals in parts of central Africa, are both
usually indolent tumors which mainly affect the skin. KS asso-
ciated with immunosuppression caused by HIV and iatrogenic
KS after an organ transplant are more aggressive forms of the
disease and can affect systemic organs (6). DNA belonging to
a novel gammaherpesvirus was isolated from a primary AIDS-
associated KS biopsy (12). Since then, evidence that implicates
this KS-associated herpesvirus (KSHV or human herpesvirus
8) as the cause of KS has accumulated. Viral DNA is found in
KS lesions of all epidemiological forms of the disease (i.e.,
classic, endemic, AIDS-associated, and posttransplant KS) (1,
8, 9, 17, 37, 48), and detection of KSHV DNA in peripheral
blood of HIV-infected individuals by PCR predicts the subse-
quent development of KS. Furthermore, first-generation sero-
logical assays suggest that KSHV is not ubiquitous but is con-
fined mainly to those at risk for developing KS (24, 25, 34, 51).
Sequencing of the viral genome has demonstrated colinearity
with the oncogenic gammaherpesviruses Epstein-Barr virus
(EBV) and herpesvirus saimiri (HVS), a simian herpesvirus
that causes fulminant lymphoproliferation in New World pri-
mates (36, 37). Like EBV, KSHV infects CD191 lymphocytes
(1, 31). KSHV is also found in cells from primary effusion
lymphomas, a rare form of B-cell lymphoma seen mainly in
patients with advanced AIDS (10). The lymphatic system ap-
pears to be the primary site of KSHV replication, while in KS
tumors the virus is found in a latent, nonlytic state with only a
subset of its genes expressed (14, 44, 58).
KSHV lacks several genes implicated in EBV-induced cell
immortalization and oncogenesis (such as those encoding
EBNA-1 and -2, LMP-1 and -2, and Gp 350/220) and two genes
implicated in HVS transformation (those encoding StpC and
Tip) (46). However, KSHV encodes other genes whose prod-
ucts could play a role in tumor induction, including a bcl-2
homolog, genes encoding chemokines interleukin-6, macro-
phage inflammatory protein, an interferon regulatory factor,
an interleukin-8 receptor, and an NCAM-like protein (35, 46,
47), and a gene with cyclin homology (11), similar to that
encoded by HVS (39). Transcripts encoding this cyclin are
found in KS tumor cells and cells from primary effusion lym-
phomas, suggesting that the product of this gene could be
involved in KS and lymphoma tumorigenesis (7a, 11).
Like the HVS cyclin, the cyclin encoded by KSHV (KSHV-
cyc) is closest related in sequence to the cellular type D cyclins
(11, 39) suggesting that these viral cyclins may be evolutionar-
ily derived from this subgroup of cellular cyclins.
Cellular cyclins are components of kinases, many of which
regulate cell proliferation and cell cycle progression (reviewed
in references 21, 41, and 49). When ectopically expressed in
tissue culture cells, the cell cycle-regulating G1 cyclins D and E
accelerate transit through the G1 phase of the cell cycle, and
the mitotic type B cyclin has been associated with cellular
hyperproliferation in plants (15, 45, 54; reviewed in reference
16). Moreover, the aberrant expression of cellular type D cy-
clins is strongly implicated in various human cancers (7, 20, 27;
reviewed in references 5, 20, 21, 41, and 50). A hallmark of
cyclins is their ability to associate with and activate cellular
kinase subunits (cyclin-dependent kinases [cdks]) (reviewed in
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reference 38). When active, certain of these kinases phosphor-
ylate cell cycle checkpoint molecules and thereby facilitate
progression of cells through the cell cycle. The KSHV-encoded
cyclin-like gene, when ectopically expressed in cells, promotes
phosphorylation of the retinoblastoma protein (pRB) and can
overcome a cell cycle checkpoint imposed by this tumor sup-
pressor (13), suggesting that the encoded cyclin protein may
act to stimulate cellular cdks and, in ways analogous to cell
cycle-regulating cellular cyclins, promote cell cycle progres-
sion.
We provide evidence here that the KSHV-cyc functions as a
genuine cyclin protein. Upon expression in Cos cells or insect
cells it stimulates cdk6, a kinase subunit normally activated by
the cellular type D cyclins. KSHV-cyc-activated cdk6, however,
has features divergent from those inherent to cyclin D-acti-
vated cdk6 and therefore may fulfill functions beyond those
elicited by cellular cyclin D-cdk6 complexes.
MATERIALS AND METHODS
Materials. A 9E10 (c-myc) epitope-tagged version of the KSHV-cyc was gen-
erated by PCR, using a cloned genomic fragment of KSHV covering open
reading frame (ORF) 72 (11) as a template. SacI/XbaI and NotI sites were
attached to the 59 and 39 ends, respectively, using the following primers: 59
gcatgagctctagatggcaactgccaataacc 39 and 59 gcatgcggccgccatagctgtccagaatgcgc 39.
The 39 primer was designed such that the natural stop codon of ORF 72 was
deleted. A cloned version of the 9E10 (c-myc) epitope (coding for amino acids
EQLISEEDL-stop) was subsequently inserted into the 39 NotI site. Similarly, a
NotI site was introduced via PCR prior to the stop codon of human cyclins D1,
D2, and E to facilitate in-frame insertion of the above 9E10 epitope sequence.
Cloned versions of human cyclin D1 and D2 were provided by G. Peters (Im-
perial Cancer Research Fund London, England). Epitope-tagged cyclins were
cloned into RcCMV (Invitrogen, San Diego, Calif.) for expression in mammalian
cells or pVL1392/3 (PharMingen, San Diego, Calif.) to generate cyclin-express-
ing baculovirus. Baculovirus encoding cdk4 was obtained from C. Sherr (Howard
Hughes Medical Institute St. Jude’s Hospital, Memphis, Tenn.). Cloned versions
of human cdk2, cdk5, and cdk6 were obtained from E. Harlow (Massachusetts
General Hospital, Charlestown, Mass.) and engineered into pVL1392/3 to gen-
erate baculovirus. Baculoviruses were produced by using a Baculovirus Gold kit
(PharminGen). A construct allowing expression of human p27 (KIP) as a gluta-
thione S-transferase (GST) fusion in Escherichia coli was obtained from T.
Hunter (Salk Institute, La Jolla, Calif.).
Specific anti-cdk rabbit sera were purchased from Upstate Biotechnology, Inc.
(Lake Placid, N.Y.) (cdk2) or Santa Cruz Biotechnology (Santa Cruz, Calif.)
(cdk4, cdk6, and cdk5).
Characterization of KSHV-cyc by Cos cell transfection. Cos cells were trans-
fected with plasmid via DEAE dextran-mediated DNA transfer essentially as
described previously (26). To determine the intracellular distribution of the
KSHV-cyc, transfected Cos cell monolayers or MDCK cells microinjected with
plasmid encoding 9E10 epitope-tagged KSHV-cyc were fixed in 4% paraformal-
dehyde, permeabilized with 0.1% Triton, and reacted with 9E10 antibody fol-
lowed by fluorescein isothiocyanate (FITC)-coupled anti-mouse antibody. Cell
monolayers were examined by confocal microscopy.
Lysates were prepared from transfected Cos cells 42 h posttransfection in HB
(50 mM HEPES-NaOH [pH 7.4]–150 mM NaCl–20 mM EDTA–0.5% Triton
X-100–2 mM dithiothreitol with 1% aprotinin, 2.5 mg of leupeptin per ml, and 1
mM phenylmethylsulfonyl fluoride [PMSF] to inhibit proteases and 10 mM NaF,
10 mM b-glycerophosphate, and 1 mM sodium vanadate to inhibit phospha-
tases), using 150 ml per 106 cells. Lysis was performed on ice, and lysates were
cleared by centrifugation (10 min at 10,000 3 g, 4°C).
Expression of the 9E10 epitope-tagged cyclins was monitored by probing
Western blots with 9E10 antibody followed by horseradish peroxidase-coupled
mouse-specific secondary antibody (Amersham, Little Chalfont, England) and
enhanced chemiluminescence (Amersham).
For immunoprecipitation of epitope-tagged cyclins, 30 ml of cleared lysate was
diluted with 500 ml of HB and reacted for 2 h with 20 mg of 9E10 antibody
prebound to 15 ml of protein G-agarose (Sigma, Poole, England). The immuno-
complexes were washed three times in HB and analyzed by Western blotting for
copurifying cdk subunits.
For measurement of kinase activity, beads were washed once in kinase buffer
(50 mM HEPES-KOH [pH 7.4]–10 mM MgCl2–10 mM MnCl2–1 mM dithio-
threitol containing 0.1 mM protein kinase A inhibitor [Sigma], 10 mM b-glyc-
erophosphate, 1% aprotinin, 1 mM PMSF, and 2.5 mg of leupeptin per ml).
Kinase assays were performed by adding 15 ml of kinase buffer, containing 500 ng
of substrate, 10 mM ATP, and 0.1 mCi of [g-32P]ATP, directly to the bead pellet.
For a substrate, we used either purified histone H1 (a gift of G. Goodwin,
Institute of Cancer Research, London, England), full-length pRB, or a fragment
(amino acids 763 to 928) covering the cluster of cdk consensus phosphorylation
sites in the carboxy terminus of pRB, both expressed as GST fusions in E. coli.
GST-pRB fusion proteins were constructed and purified as described previously
(57). Kinase reactions were allowed to proceed for 10 min at 27°C, after which
time the reaction was terminated by adding sodium dodecyl sulfate (SDS)-
containing gel loading buffer. Reactions were separated on SDS-polyacrylamide
gels. Gels were fixed in 40% methanol–10% acetic acid, dried, and exposed to
X-ray film. Signals were quantified with a phosphorimager.
Lysates were depleted for individual cdks by treatment with 20 mg of anti-cdk
antiserum bound to protein A-agarose (Bethesda Research Laboratories, Gaith-
ersburg, Md.). Depleted lysates were subsequently subjected to 9E10 precipita-
tion, and the resulting precipitates were assayed for kinase activity.
For p27 (KIP) inhibition, lysate was mixed with purified GST-p27 followed by
incubation at room temperature for 15 min. Cyclins were immunoprecipitated
from these lysates, and kinase activity was determined as described above.
Expression of KSHV-cyc and stimulation of cdk activity in insect cells. Spo-
doptera frugiperda SF9 insect cells were cultured and infected with baculovirus by
using standard procedures, with modifications as described previously (57). Ex-
tracts from virus-infected cells were prepared 40 h postinfection. Cells were
collected by centrifugation (800 3 g for 10 min, 4°C) and lysed in hypotonic
buffer (10 mM HEPES-KOH [pH 7.0]–10 mM KCl–1 mM EDTA containing
protease inhibitors PMSF, aprotinin, and leupeptin and phosphatase inhibitors
b-glycerophosphate, NaF, and sodium vanadate at concentrations indicated
above), using 100 ml per 5 3 106 cells. Prior to the kinase assay, the hypotonic
lysate was diluted fivefold in kinase buffer, and insoluble material was removed
by centrifugation (10,000 3 g, 10 min, 4°C). Kinase reactions were performed as
described above, using 5 ml of diluted insect cell extract per reaction.
RESULTS
Expression of KSHV-cyc in Cos cells. To study the biochem-
ical properties of the KSHV-encoded cyclin, we engineered a
cyclin version tagged at the carboxy terminus with a 9E10
(c-myc) epitope. When probing lysates from Cos cells trans-
fected with plasmid to express this cyclin with the tag-specific
antibody 9E10, we detected a reactive protein with a molecular
mass (28 kDa) close to that predicted for the 257-amino-acid-
long KSHV-cyc ORF (Fig. 1a).
Immunofluorescence on Cos cells transfected, or MDCK
cells microinjected, with this cyclin-expressing plasmid demon-
strated that the encoded cyclin protein is found predominantly
in the nuclear compartment (Fig. 1b), a subcellular localization
common to cellular G1/S cyclins (3, 28, 40).
When immunopurified via the epitope tag from extracts of
transfected Cos cells, KSHV-cyc copurified with kinase activity
(Fig. 2) capable of phosphorylating classical cyclin D substrates
such as full-length pRB and a C-terminal fragment of pRB.
However, in contrast to reports on cyclin D-associated kinases
(29, 30), the KSHV-cyc-associated activity is also able to phos-
phorylate histone H1.
Inhibition of KSHV-cyc-associated kinases by p27 (KIP). To
gain evidence for whether the activity associated with KSHV-
cyc was due to stimulation of cellular cdks, we tested whether
this kinase activity was affected by p27 (KIP), a cellular cdk
inhibitor that regulates a wide variety of cyclin-cdk complexes,
including those containing cellular D, E, and A cyclins (19, 42,
43, 53). We found that recombinant p27, when added to cel-
lular extracts containing KSHV-cyc, acted as a potent repres-
sor of both the histone H1 and pRB kinase activities associated
with this cyclin (Fig. 3). This result suggests that the majority of
activity associated with KSHV-cyc is mediated by p27-sensitive
kinase subunits. We note that a residual amount of both his-
tone H1 and pRB kinase activity remained detectable in pre-
cipitates of KSHV-cyc even at a high concentration of p27.
Using phosphorimager-based analysis, we determined that be-
tween 5 and 7% of the initial activity was retained in immu-
noprecipitates treated with a saturating amount of p27, i.e., the
amount required to achieve maximal kinase inhibition (5 nM).
No further decrease of activity could be achieved even when
the p27 concentration was increased 25-fold. In contrast, the
activity associated with cellular cyclin E (epitope-tagged and
expressed in Cos cells like KSHV-cyc) was completely blocked
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by 5 nM p27. These data raise the possibility that a small
portion of the activity associated with the viral cyclin is medi-
ated via a p27-resistant kinase.
Association of KSHV-cyc with cdk subunits. To identify
which cdk subunits bind to and may be activated by KSHV-cyc,
we probed KSHV-cyc immunoprecipitates from transfected
Cos cells with antisera that specifically recognize individual
cdks. To determine the specificity of our assay, we examined, in
parallel, cellular cyclins known to complex with distinct subsets
of these cdks. As with KSHV-cyc, all of these cellular cyclins
were engineered to express the 9E10 epitope tag at their car-
boxy termini.
For the experiment shown in Fig. 4, precipitates for these
individual cyclins were divided into four equal aliquots and,
following separation on SDS-gels, probed with different anti-
cdk antisera. We found that both cdk5 and cdk6 efficiently
copurified with KSHV-cyc. Both of these cdks, in agreement
with earlier reports (4, 29, 33, 55), also copurified with the
cellular cyclins D1 and D2 but not with cyclin E (Fig. 4). We
further detected a very small amount of cdk2 in complexes with
KSHV-cyc. Interestingly, we did not detect association of this
cyclin with cdk4, a kinase subunit that is very closely related in
sequence to cdk6 (32, 33) and which, in accord with previous
reports, efficiently copurified with the cellular type D cyclins
(Fig. 4). These results suggest that KSHV-cyc can bind to a
panel of cdks similar but not identical to those associating with
cellular type D cyclins.
FIG. 1. Expression of epitope-tagged KSHV-cyc in Cos and MDCK cells. (a)
Western blot detecting epitope-tagged KSHV-cyc in extracts of transfected Cos
cells. Cos cells were transfected with vector alone (lane 1) or vector encoding
KSHV ORF 72 (KSHV-cyc) (lane 2). Cell extracts were subjected to Western
analysis using tag-specific 9E10 antibody. (b) Immunolocalization of epitope-
tagged KSHV-cyc in Cos cells or the canine kidney-derived cell line MDCK.
Vector encoding epitope-tagged KSHV-cyc was transfected into Cos cells or
microinjected into MDCK cells. Cells were fixed 42 h later and probed with the
9E10 antibody and FITC-labelled secondary antibody. Photomicrographs show
transfected Cos cells (top) and MDCK cells (bottom) with FITC fluorescence
(left) and phase contrast of the corresponding area (right).
FIG. 2. Phosphorylation of pRB and histone H1 by immunopurified KSHV-
cyc in vitro. Lysates from Cos cells transfected with either expression vector
encoding tagged KSHV-cyc (RcCMV.v-cyc) or vector alone (RcCMV) were
subjected to immunoprecipitation using 9E10 antibody. Kinase activity associ-
ated with these immunoprecipitates was measured by using bacterially produced
full-length human pRB (lanes 1 and 2), a fragment (amino acids 763 to 928)
covering the carboxy terminus (c-term) of human pRB (lanes 3 and 4), or histone
H1 (lanes 5 and 6) as a substrate.
FIG. 3. Inhibition of KSHV-cyc-associated kinase activity by recombinant
p27 (KIP). Lysates from Cos cells transfected with epitope-tagged KSHV-cyc or
tagged human cyclin E were treated with increasing amounts of recombinant p27
protein and precipitated with tag-specific 9E10 antibody. The concentrations of
p27 used were 5 nM (lanes 3 and 7), 25 nM (lanes 4 and 8), and 125 nM (lanes
5 and 9). For a control, 250 nM unfused GST protein was added in place of the
p27 (lanes 2 and 6). Kinase activity in the immunoprecipitates was measured by
using a carboxy-terminal fragment of pRB (top) or histone H1 (bottom) as a
substrate.
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Specific activation of cdk6 by KSHV-cyc. To determine
which, if any, of the cdk subunits associated with KSHV-cyc
was responsible for the observed kinase activities, we used
cdk-specific antibodies to remove individual cdks from KSHV-
cyc-containing Cos cell lysates. We then precipitated for the
viral cyclin by using the tag-specific antibody and assayed the
resulting immunoprecipitates for kinase activity by using either
histone H1 or pRB as a substrate. Figure 5 shows that the
kinase activities directed against pRB and histone H1 were
greatly reduced (i.e., by 96 and 91%, respectively, as quantified
by phosphorimager analysis) when lysates were precleared with
the anti-cdk6 antibody. Preclearing with either the anti-cdk5
serum or a serum against cdk4 or cdk2 had no effect. This
result suggests that the vast majority of kinase activity associ-
ated with the viral cyclin in transfected Cos cells is mediated
via complexes that contain cdk6. Furthermore, our results sug-
gest that these cdk6 complexes not only are responsible for
pRB phosphorylation but also mediate the phosphorylation of
histone H1.
cdk activation in insect cells. To ascertain that our results
reflect genuine biochemical features of KSHV-cyc, we sought
to confirm our findings by an independent approach, namely,
baculovirus-directed expression in insect cells. We generated
recombinant baculovirus expressing 9E10 epitope-tagged
KSHV-cyc and studied the ability of this virus to facilitate
kinase activation upon coinfection with baculoviruses encoding
individual cdks (Fig. 6). To compare the features of the viral
cyclin with those of cellular type D cyclins, we also engineered
a virus encoding 9E10-tagged cellular cyclin D1. Infection of
insect cells with virus encoding either of these cyclins alone or
various cdk catalytic subunits alone resulted in only a low level
of background activity. Kinase activity significantly above this
background level was seen when virus encoding KSHV-cyc was
used in combination with cdk6 and, to a lesser extent, in con-
junction with cdk4, but not with cdk2 or cdk5. Similarly, com-
bined infection of cdk4 or cdk6 with cellular cyclin D1 resulted
in increased kinase activity. Probing of the lysates by using
cdk-specific antibodies demonstrated that similar levels of cdk4
and cdk6 catalytic subunits were expressed in singly and doubly
infected cells, indicating that the increase in kinase activity
upon cyclin coinfection was not due to differences in expres-
sion of these cdks but reflect a genuine increase in their specific
activities.
Significantly, we found that the kinase activity evoked upon
coexpression of KSHV-cyc with cdk6 (and also cdk4) was ca-
pable of phosphorylating efficiently both pRB and histone H1.
This is in stark contrast to the situation seen when cellular
cyclin D1 is coexpressed with these cdk subunits. The kinase
activity generated under these conditions was specific to pRB
and did not yield histone H1 phosphorylation above the back-
ground level.
Thus, in agreement with our results for Cos cells, expression
of the KSHV-cyc in insect cells results in efficient stimulation
of cdk6. However, in insect cells, where both kinase subunit
and cyclin are overexpressed, this cyclin appears also capable
of stimulating cdk4. More importantly, activation via KSHV-
cyc appears to modify the substrate preference of these cdk
subunits to accept substrates that are not efficiently phosphor-
ylated when these cdks are activated via cellular type D cyclins.
DISCUSSION
Our results demonstrate that the cyclin-like reading frame
encoded by KSHV can operate as a genuine cyclin in that it can
associate with and activate cdk catalytic subunits. When ec-
topically expressed in tissue culture cells, it complexes with a
FIG. 4. Association of KSHV-cyc with cellular cdk subunits. Cos cells were
transfected with plasmids encoding tagged KSHV-cyc, a panel of tagged cellular
cyclins, or vector alone. Lysates were prepared 42 h after transfection and
subjected to 9E10 immunoprecipitation. Immunocomplexes were separated on
SDS-polyacrylamide gels followed by Western blotting. Individual cdk subunits
were detected by using specific antipeptide antisera as indicated. RcCMV.D1,
RcCMV.D2 and RcCMV.E refer to vectors encoding human cyclin D1, human
cyclin D2, and human cyclin E, respectively.
FIG. 5. Kinase activity is mediated by the KSHV-cyc–cdk6 complex. Lysates
from transfected Cos cells were depleted for individual cdks by using cdk-specific
antisera (indicated by a). Subsequently, depleted lysates were subjected to 9E10
precipitation. Kinase activity associated with the 9E10 precipitate was deter-
mined by using either a carboxy-terminal pRB fragment (top) or histone H1
(bottom) as a substrate. Cells were transfected with KSHV-cyc-encoding plasmid
(RcCMV.v-cyc) or vector alone (RcCMV) as indicated.
FIG. 6. cdk activation in insect cells. (a) Insect cells were infected with
recombinant baculoviruses as indicated. Kinase activity was determined in ex-
tracts from infected cells by using the carboxy terminus of pRB (top) or histone
H1 (bottom) as a substrate. (b) Extracts were probed for expression of the
individual cdks by using combinations of cdk-specific antisera (indicated by a) as
indicated.
4196 GODDEN-KENT ET AL. J. VIROL.
set of kinases similar but not identical to those bound by
cellular type D cyclins. The kinase activity associated with this
viral cyclin appears to be mediated largely through cdk6. Al-
though we found that also cdk5 associates with this cyclin, the
significance of this is not clear, as complexes containing cdk5
appear not to generate activity (at least when assayed under
the conditions used). This finding parallels observations with
cellular type D cyclins. While association of these cyclins with
cdk5 can be demonstrated (reference 56 and this report), ac-
tivity of such cyclin D-cdk5 complexes has not been reported to
date.
Interestingly, the kinase activity associated with the KSHV-
cyc–cdk6 complex catalyzes efficiently phosphate transfer onto
both histone H1 and pRB. This contrasts with results obtained
for the cyclin D-cdk6 complex, the substrate specificity of
which appears confined to pRB itself and a few pRB-related
proteins, and which is virtually incapable of phosphorylating
histone H1 (reference 33 and this report). Such confined sub-
strate preference may reflect the fact that type D cyclins are
specifically designed to catalyze progression through the G1
phase of the cell cycle. The ability of the KSHV-cyc–cdk com-
plex to target additional substrates, however, opens the possi-
bility that this kinase is able to fulfill functions other than
promoting G1 progression, e.g., to mediate progression
through further checkpoints imposed later in the cell cycle.
Various features of KSHV-cyc appear to closely resemble
those previously described for the cyclin encoded by HVS (23).
Like KSHV-cyc, the cyclin encoded by HVS associates with
and activates cdk6 in insect cells, and like the kinase activated
by KSHV-cyc, this kinase can phosphorylate histone H1. Such
conservation of biochemical features appears remarkable, in
particular when one considers that the amino acid conserva-
tion between these two viral cyclins is moderate—only 33% of
their amino acids are identical (11). Despite error-prone viral
replication, these biochemical features appear to have been
preserved, perhaps indicating their importance for the func-
tioning of these cyclins in the context of virus propagation. An
interesting question may be how these biochemical features
were derived in the first place. Likely, the viral cyclins are
descendants of an ancient type D cyclin scavenged by these
viruses from their hosts. The features of the viral cyclins could
reflect characteristics of this ancient cyclin D precursor or,
alternatively, comprise adaptations to a special need of these
viruses. The function of the virally encoded cyclins in virus
propagation is not clear, though an obvious possibility lies in
the need for these viruses to overcome cell cycle restrictions
upon infection of resting host cells.
Methods of triggering cell proliferation have independently
evolved in a wide variety of other DNA viruses. For example,
the papillomavirus E6 and E7 proteins, adenovirus E1A and
E1B, and polyomavirus-encoded T antigens all bind and inac-
tivate pRB and the tumor suppressor p53 (for reviews, see
references 18 and 22), while two of EBV’s immortalizing genes
(encoding EBNA-2 and LMP-1) promote cell cycle progres-
sion via the induction of cellular G1 cyclins (2, 52). Viruses may
require genes that modulate cellular growth to execute their
replication cycle. However, many of these growth-promoting
genes elicit tumorigenic effects when expressed in isolation or
in the absence of lytic virus replication.
An important cofactor for the establishment of KSHV-as-
sociated tumors is immunodeficiency, and this condition ap-
pears to determine the severity and clinical presentation of the
disease (6). In KSHV-infected individuals, occasional infection
of cells that cannot support virus replication may occur. While
such cells would be eliminated in immunocompetent hosts, in
immunocompromised individuals they may prevail and as a
result of residual viral gene expression adopt a quasi-tumor-
ous, hyperproliferative nature. The cyclin-like reading frame is
one of the few genes transcribed under such conditions. By
aberrantly stimulating cellular cdks, it may trigger cell cycle
progression and thereby contribute to the pathogenesis of KS.
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